Literature DB >> 33065471

Andrographolide suppresses cisplatin-induced endothelial hyperpermeability through activation of PI3K/Akt and eNOS -derived nitric oxide.

Vijaya Lakshmi Bodiga1, Jagadeesh Bathula2, Madhukar Rao Kudle3, Praveen Kumar Vemuri4, Sreedhar Bodiga5.   

Abstract

Cisplatin upregulate the intercellular adhesion molecule expression on the surface of endothelium, which in turn mediates enhanced infiltration by monocytes or leukocytes, resulting in endothelial dysfunction. Here we examined changes induced by andrographolide, a diterpenoid lactone isolated from Andrographis paniculata on endothelial cell activation and hyperpermeability in cisplatin-stimulated endothelial cells. Cisplatin upregulated endothelial ICAM-1 expression, through an NF-κB dependent mechanism, that also required the enhanced translocation of Protein Kinase C-α (PKC) onto the plasma membrane, phosphorylation of transient receptor potential channel 1 (TRPC), leading to store-operated Ca2+-entry (SOCE), endothelial cell dysfunction and hyperadhesion of U937 monocytes. Pretreatment of endothelial cells with andrographolide prior to stimulation with cisplatin resulted in activation of PI3K/Akt and eNOS, production of nitric oxide (NO) and cGMP, with a consequential lowering of endothelial cell leakiness and improved transendothelial electrical resistance. Andrographolide-induced NO was essential for NF-κB inhibition, lowered ICAM-1 expression as well as prevention of SOCE and reduced the U937 binding to cisplatin-stimulated endothelial cells.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Andrographis paniculata; Cell adhesion; Cisplatin; Endothelial permeability

Mesh:

Substances:

Year:  2020        PMID: 33065471     DOI: 10.1016/j.bmc.2020.115809

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  The Role of Vascular-Immune Interactions in Modulating Chemotherapy Induced Neuropathic Pain.

Authors:  Tameille Valentine; Lydia Hardowar; Jasmine Elphick-Ross; Richard P Hulse; Mark Paul-Clark
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.